A phase II randomized study of lenalidomide or lenalidomide and rituximab as maintenance therapy following standard chemotherapy for patients with high/high-intermediate risk diffuse large B-cell lymphoma.
N. M. Reddy
No relevant relationships to disclose
R. Simmons
No relevant relationships to disclose
M. Caldwell
No relevant relationships to disclose
M. H. Jagasia
No relevant relationships to disclose
D. S. Morgan
No relevant relationships to disclose
S. I. Park
No relevant relationships to disclose
J. P. Greer
No relevant relationships to disclose
K. L. Richards
No relevant relationships to disclose